Determining a predisposition to cancer
The present invention relates to methods and kits for determining a predisposition for developing cancer, e.g., prostate and/or breast cancer, due to a germline mutation of a NBS1 gene. The present invention also relates to surveillance protocols for developing cancer, e.g., prostate and/or breast cancer, due to germline mutation of a NBS1 gene.
1. A method for detecting a predisposition to prostate cancer in a human subject, comprising: (a) detecting in a biological sample from the human subject germline alteration 657de15 in the sequence of a NBS1 gene; and (b) associating the alteration with a predisposition to prostate cancer in the human subject, thereby detecting the predisposition.
2. The method of claim 1 , wherein the alteration is present in the sequence of a single allele of the NBS1 gene.
3. The method of claim 1 , wherein the alteration is present in the sequence of two alleles of the NBS1 gene.
4. The method of claim 1 , wherein the human subject is of Slavic origin.
5. The method of claim 1 , wherein the alteration is detected by microchip, ASO PCR, SSCP, direct sequencing, ASA, or RFLP-PCR.
6. The method of claim 1 , wherein the predisposition is an inherited predisposition.
7. The method of claim 1 , wherein the biological sample is biological material of any kind.
8. The method of claim 7 , wherein the biological sample is blood.
9. The method of claim 1 , wherein the biological sample comprises leukocytes.